TY - JOUR T1 - MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 117 LP - 117 DO - 10.1136/dtb.2019.000032 VL - 57 IS - 8 A2 - , Y1 - 2019/08/01 UR - http://dtb.bmj.com/content/57/8/117.abstract N2 - Review of: Medical and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene. Drug Safety Update 2019;12(7):3.Key learning pointsNecrotising fasciitis of the genitalia or perineum has been reported in people taking sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes.If gangrene is suspected, treatment with SGLT2 inhibitors should be stopped and treatment for gangrene (including antibiotics and surgical debridement) started immediately.Urogenital infection or perineal abscess may precede necrotising fasciitis.Prescribers and patients are … ER -